Our lead drug candidate, CNM-Au8®, is currently in development as a disease-modifying treatment for people living with Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson’s Disease (PD).
CNM-Au8® is an oral suspension of clean-surfaced, catalytically-active, highly-faceted gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. Orally-administered, CNM-Au8® has demonstrated safety in humans in Phase 1 studies (NCT02755870), and has been shown to have remyelination and neuroprotective effects in preclinical models1. CNM-Au8® crosses the blood-brain barrier and is not associated with the toxicities related to synthetic gold compounds or nanoparticles manufactured via alternative methods. There have been over 300 patient years of CNM-Au8® exposure without identified safety signals.
1Robinson, A. P. et al. Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis. Sci Rep 10, 1936 (2020).